[1]
|
Ben-Chetrit E, Gattorno M, Gul A, et al. Consensus Proposal for Taxonomy and Definition of the Autoinflamma-tory Diseases (AIDs): A Delphi Study[J]. Ann Rheum Dis, 2018, 77: 1558-1565. doi: 10.1136/annrheumdis-2017-212515 |
[2]
|
Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee[J]. J Clin Immunol, 2022. doi: 10.1007/s10875-022-01289-3. |
[3]
|
Graham R, Mancher M, Miller WD, et al. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust[M]. Washington DC: National Academies Press, 2011. |
[4]
|
Sinclair D, Isba R, Kredo T, et al. World Health Organization Guideline Development: An Evaluation[J]. PLoS One, 2013, 8: e63715. doi: 10.1371/journal.pone.0063715 |
[5]
|
Brouwers MC, Kerkvliet K, Spithoff K, et al. The AGREE Reporting Checklist: A Tool to Improve Reporting of Clinical Practice Guidelines[J]. BMJ, 2016, 352: i1152. |
[6]
|
Chen Y, Yang K, Marušic A, et al. A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement[J]. Ann Intern Med, 2017, 166: 128-132. doi: 10.7326/M16-1565 |
[7]
|
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: A Critical Appraisal Tool for Systematic Reviews That Include Randomised or Non-Randomised Studies of Healthcare Interventions, or Both[J]. BMJ, 2017, 358: j4008. |
[8]
|
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials[J]. BMJ, 2011, 343: d5928. doi: 10.1136/bmj.d5928 |
[9]
|
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: A Tool for Assessing Risk of Bias in Non-Randomised Studies of Interventions[J]. BMJ, 2016, 355: i4919. |
[10]
|
Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies[J]. Ann Intern Med, 2011, 155: 529-536. doi: 10.7326/0003-4819-155-8-201110180-00009 |
[11]
|
Stang A. Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses[J]. Eur J Epidemiol, 2010, 25: 603-605. doi: 10.1007/s10654-010-9491-z |
[12]
|
Rostom A, Dubé C, Cranney A, et al. Appendix D. Quality Assessment Forms[M]. Rockville (MD): Agency for Healthcare Research and Quality (US), 2004. |
[13]
|
Institute of Health Economics (IHE). Quality Appraisal of Case Series Studies Checklist[EB/OL] (2016-03-02)[2023-02-13]. http://www.ihe.ca/research-programs/rmd/cssqac/cssqac-about. |
[14]
|
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations[J]. BMJ, 2008, 336: 924-926. doi: 10.1136/bmj.39489.470347.AD |
[15]
|
ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the Management of Autoinflammatory Diseases[J]. Ann Rheum Dis, 2015, 74: 1636-1644. doi: 10.1136/annrheumdis-2015-207546 |
[16]
|
Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, et al. Diagnostic Criteria for Cryopyrin-Associated Periodic Syndrome (CAPS)[J]. Ann Rheum Dis, 2017, 76: 942-947. doi: 10.1136/annrheumdis-2016-209686 |
[17]
|
Hansmann S, Lainka E, Horneff G, et al. Consensus Protocols for the Diagnosis and Management of the Hereditary Autoinflammatory Syndromes CAPS, TRAPS and MKD/HIDS: A German PRO-KIND Initiative[J]. Pediatr Rheumatol Online J, 2020, 18: 17. doi: 10.1186/s12969-020-0409-3 |
[18]
|
Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist[J]. Ann Rheum Dis, 2022, 81: 907-921. doi: 10.1136/annrheumdis-2021-221801 |
[19]
|
Cetin Gedik K, Lamot L, Romano M, et al. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI and AGS[J]. Ann Rheum Dis, 2022, 81: 601-613. doi: 10.1136/annrheumdis-2021-221814 |
[20]
|
Shinar Y, Ceccherini I, Rowczenio D, et al. ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the next-Generation Sequencing Era[J]. Clin Chem, 2020, 66: 525-536. doi: 10.1093/clinchem/hvaa024 |